Every Form 4 that Urogen Pharma (URGN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow URGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full URGN filings page.
UroGen Pharma Ltd. (URGN) director James A. Robinson Jr. reported the exercise and settlement of equity awards. On 2026-08-26, he exercised 2,000 Restricted Stock Units, each representing a contingent right to receive one ordinary share, which converted into 2,000 ordinary shares of UroGen.
The derivative RSU position of 2,000 units was fully settled, leaving no RSUs from this award outstanding, and Mr. Robinson’s directly held ordinary shares increased to 8,000 shares following the transaction.
UroGen Pharma Ltd. (URGN) reported that Chief Medical Officer Mark Schoenberg sold 60,677 ordinary shares on 2026-08-20 in an open market or private transaction. The weighted average sale price was $47.05 per share, with prices ranging from $46.30 to $49.70. Following the sale, Schoenberg directly holds 59,086 ordinary shares.
UroGen Pharma Ltd. Chief Medical Officer Mark Schoenberg reported an open-market sale of 10,000 Ordinary Shares of URGN at a weighted average price of $40.00 per share. The transaction was made pursuant to a duly adopted Rule 10b5-1(c) trading plan and represents the final sale under that plan. Following this sale, Schoenberg holds 119,763 Ordinary Shares directly.
UroGen Pharma Ltd. Chief Medical Officer Mark Schoenberg sold 10,000 Ordinary Shares in an open-market transaction at a weighted average price of $35.01 per share, with trades ranging from $35.00 to $35.08, under a pre-adopted Rule 10b5-1(c) trading plan. Following this sale on June 22, 2026, he directly holds 129,763 Ordinary Shares.
UroGen Pharma director Daniel George Wildman received new equity awards. He was granted 8,000 restricted stock units and stock options for 10,000 ordinary shares at an exercise price of $34.99 per share. Both the RSUs and options vest in equal quarterly installments over one year, contingent on his continuous service.
UroGen Pharma Ltd. director James A. Robinson Jr. reported equity awards that increase his potential ownership in the company. On June 22, 2026, he received 8,000 restricted stock units (RSUs), each representing one ordinary share upon vesting. He was also granted stock options on 10,000 ordinary shares with an exercise price of $34.99 per share and an expiration date of June 22, 2036. Both the RSUs and the option shares vest in equal quarterly installments over one year, contingent on his continued board service. After these grants, his reported holdings from these awards are 8,000 RSUs and 10,000 options, reflecting routine director compensation rather than open‑market trading.
UroGen Pharma Ltd. director Stuart Holden received a grant of stock options covering 20,000 ordinary shares. The options have an exercise price of $34.99 per share, expire on June 22, 2036, and vest in equal quarterly installments over one year, subject to his continuous service. Following this grant, he holds 20,000 options directly.
UroGen Pharma Ltd. director Cynthia M. Butitta received new equity awards as part of her compensation. She was granted 8,000 restricted stock units, each representing a right to receive one ordinary share. These RSUs will vest in equal quarterly installments over one year, so the award is earned gradually as service continues.
She was also granted stock options covering 10,000 ordinary shares at an exercise price of $34.99 per share, expiring on June 22, 2036. The option shares vest in equal quarterly installments over one year, aligning her incentives with long‑term shareholder value rather than reflecting any open‑market buying or selling.
UroGen Pharma Ltd. director Leana Wen reported receiving new equity awards as part of her compensation. She was granted 8,000 restricted stock units, each representing a right to receive one ordinary share, and 10,000 stock options to purchase ordinary shares at an exercise price of $34.99 per share.
The RSUs and the shares underlying the options will vest in equal quarterly installments over one year, contingent on her continued service under the company’s 2017 Equity Incentive Plan. These are grants and do not involve any open-market buying or selling of shares.
UroGen Pharma Ltd. director Arie Belldegrun received a grant of stock options covering 20,000 ordinary shares. These options were granted at an exercise price of $34.99 per share and expire on June 22, 2036. The underlying 20,000 ordinary shares will vest in equal quarterly installments over one year, subject to the director maintaining Continuous Service under the company’s 2017 Equity Incentive Plan. After this grant, the filing shows 20,000 derivative securities held directly, with no additional option positions listed.
UroGen Pharma’s Chief Medical Officer Mark Schoenberg reported routine equity compensation activity. On June 8, he exercised restricted stock units (RSUs) covering 10,000 ordinary shares, converting them into stock at no exercise price. On the same date, 5,222 ordinary shares were sold at $27.30 per share to satisfy withholding tax obligations tied to this RSU settlement, according to the footnotes. After these transactions, Schoenberg directly held 139,763 ordinary shares of UroGen Pharma.
UroGen Pharma director James A. Robinson Jr. exercised restricted stock units into ordinary shares, increasing his direct share ownership. He acquired 2,000 ordinary shares through an RSU conversion and now directly holds 6,000 ordinary shares, with 2,000 RSUs remaining outstanding as a separate derivative holding.
UroGen Pharma Ltd. Chief Medical Officer Mark Schoenberg sold 10,000 Ordinary Shares in an open-market transaction. The shares were sold at a weighted average price of about $30.00 per share, with individual prices ranging from $30.00 to $30.05. After this sale, Schoenberg directly holds 134,985 Ordinary Shares. The transaction was executed pursuant to a pre-arranged trading plan adopted under Rule 10b5-1(c) on 08-15-2025, indicating it was scheduled in advance rather than timed discretionarily.
UroGen Pharma Ltd. director exercises RSUs into shares. On February 26, 2025, director James A. Robinson Jr. exercised 2,000 Restricted Stock Units, each representing a right to receive one ordinary share. This conversion resulted in the acquisition of 2,000 ordinary shares at a stated price of $0.00 per share.
After these transactions, his reported holdings increased to 4,000 Restricted Stock Units and 4,000 ordinary shares, all held directly. The activity reflects an equity award conversion rather than an open-market purchase or sale.
Barrett Elizabeth A. reported acquisition or exercise transactions in this Form 4 filing.
UroGen Pharma Ltd. reported that Chief Executive Officer Elizabeth A. Barrett received a grant of 153,195 restricted stock units on January 31, 2026. Each RSU represents the right to receive one ordinary share at no purchase price. One-third of the RSUs will vest on each of January 31, 2027, January 31, 2028, and January 31, 2029, aligning the CEO’s compensation with the company’s long-term performance.
UroGen Pharma Ltd. General Counsel Jason Drew Smith reported equity award activity and related share sales. On January 31, 2026, multiple tranches of previously granted restricted stock units (RSUs) vested and were settled into ordinary shares, including awards originally granted in 2023, 2024, and 2025.
That same day, Smith received a new grant of 32,609 RSUs, which will vest in three equal installments on January 31, 2027, January 31, 2028, and January 31, 2029. On February 3, 2026, he sold ordinary shares at $19.69 per share to cover withholding tax obligations arising from the RSU settlements, and continued to hold tens of thousands of UroGen ordinary shares directly after these transactions.
UroGen Pharma Ltd.'s Chief Medical Officer, Mark Schoenberg, reported routine share sales linked to tax withholding on equity compensation. On February 3, 2026, he sold blocks of 1,844, 1,843, and 3,686 ordinary shares at $19.69 per share.
According to the filing, these shares were sold to satisfy withholding tax obligations arising from the settlement of restricted stock units. After these transactions, Schoenberg directly beneficially owned 144,985 ordinary shares of UroGen Pharma.
UroGen Pharma Ltd. Chief Medical Officer Mark Schoenberg reported equity compensation activity involving restricted stock units (RSUs) and ordinary shares. On January 31, 2026, previously granted RSUs converted into a total of 13,333 ordinary shares at an exercise price of $0, increasing his directly held ordinary shares.
On the same date, he received a new grant of 20,000 RSUs at $0. One-third of the shares underlying this new RSU award will vest on each of January 31, 2027, January 31, 2028, and January 31, 2029, providing staged future share delivery if vesting conditions are met.
UroGen Pharma Ltd. reported that its Chief Financial Officer, Chris Degnan, received a grant of restricted stock units on January 31, 2026. The award covers 32,609 RSUs, each representing a contingent right to receive one ordinary share of UroGen Pharma.
According to the grant terms, one-third of the shares underlying the RSUs will vest on each of January 31, 2027, January 31, 2028, and January 31, 2029, subject to the standard conditions. Following this grant, Degnan beneficially owns 32,609 derivative securities directly.
UroGen Pharma Ltd. (URGN) reported an insider stock sale by its Chief Medical Officer. On 11/19/2025, the officer sold 10,000 ordinary shares in an open market transaction coded as a sale. The weighted average sale price was $25.00, with individual trades occurring between $25.00 and $25.02 per share.
The transaction was made under a pre-arranged Rule 10b5-1(c) trading plan that was adopted on 08/15/2025. After this sale, the officer directly beneficially owned 139,025 ordinary shares of UroGen Pharma.
Chris Degnan, Chief Financial Officer of UroGen Pharma Ltd. (URGN), reported equity changes related to restricted stock units. The reporting notes a grant of 13,450 RSUs on 10/08/2024 that vest in three equal annual installments beginning 10/08/2025. On 10/08/2025 the reporting person had 4,483 RSUs treated as acquired upon vesting and sold 2,203 shares to satisfy tax withholding at a price of $16.85 per share. After these transactions the beneficial ownership reported is 8,967 ordinary shares. The Form 4 was signed by an attorney-in-fact on 10/09/2025.